Caribou Biosciences, Inc. (CRBU)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-05) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | 8-K (2025-11-03) · 99.1 · 99.2 · 99.3 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | 8-K (2025-04-24) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-10) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | 8-K (2024-07-16) | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-11) · 99.1 | ||
| 10-Q/A | Q1-2023 | |||
| 10-Q/A | Q2-2023 | |||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-08) · 99.1 | 8-K (2023-07-13) · 99.1 · 99.2 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Document and Entity Information | — |
|
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (deficit) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss (P) | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Condensed Consolidated Statements of Cash Flows (P) | — |
|
| Notes | ||
| 401(k) Savings Plan | ||
| Balance Sheet Items | ||
| Commitments and Contingencies | ||
| Common Stock | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Description of The Business, Organization, and Liquidity | ||
| Fair Value Measurements and Fair Value of Financial Instruments | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Pfizer Investment | — |
|
| Related Party Transactions | ||
| Restructuring Charge | ||
| Revenue | ||
| Segment Information | — |
|
| Segment Reporting | — |
|
| Significant Agreements | ||
| Stock Based Compensation | — |
|
| Stock-based Compensation | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||